SAN DIEGO (GenomeWeb News) — Invitrogen, hoping to reverse a $130-million third-quarter loss, will make changes to its sales force leadership and restructure its commission policy, CEO Greg Luciersaid yesterday.
 
Speaking to investors at the JP Morgan Healthcare Conference in San Francisco yesterday, Lucier said Invitrogen will also consolidate its antibody manufacturing process, putting more focus on productivity, Lucier said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.